Quarterly report · Q2

Period2022-04-01 → 2022-09-30
Filed2022-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 48
MetricValuePeriodScopeSource row
Revenue¥5.5bn2022-04-01 → 2022-09-30Cons.Net sales
Revenue¥12.6bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥6.7bn2021-04-01 → 2021-09-30Cons.Net sales
Operating income¥135m2022-04-01 → 2022-09-30Cons.Operating income
Operating income¥1.6bn2021-04-01 → 2021-09-30Cons.Operating income
Ordinary income¥204m2022-04-01 → 2022-09-30Cons.Ordinary income
Ordinary income¥1.8bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥1.5bn2021-04-01 → 2021-09-30Cons.Ordinary income
Profit before tax¥157m2022-04-01 → 2022-09-30Cons.Income before income taxes
Profit before tax¥1.5bn2021-04-01 → 2021-09-30Cons.Income before income taxes
Net income (owners)¥55m2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥1.9bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥982m2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent
Net income¥55m2022-04-01 → 2022-09-30Cons.Profit loss
Net income¥976m2021-04-01 → 2021-09-30Cons.Profit loss
Total assets¥10.7bnat 2022-09-30Cons.Assets
Total assets¥10.4bnat 2022-03-31Cons.Assets
Total assets¥10.4bnat 2021-09-30Cons.Total assets (5-year summary)
Total liabilities¥4.0bnat 2022-09-30Cons.Liabilities
Total liabilities¥3.8bnat 2022-03-31Cons.Liabilities
Net assets / equity¥6.6bnat 2022-09-30Cons.Net assets
Net assets / equity¥6.6bnat 2022-03-31Cons.Net assets
Net assets / equity¥5.9bnat 2021-09-30Cons.Net assets (5-year summary)
Cash and deposits¥3.5bnat 2022-09-30Cons.Cash and deposits
Cash and deposits¥4.6bnat 2022-03-31Cons.Cash and deposits
Cash & equivalents¥3.4bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥4.6bnat 2022-03-31Cons.Cash and cash equivalents
Cash & equivalents¥3.4bnat 2021-09-30Cons.Cash and cash equivalents
Cash & equivalents¥3.0bnat 2021-03-31dCons.Cash and cash equivalents
Operating cash flow−¥696m2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥1.8bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥883m2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥601m2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Investing cash flow¥982m2021-04-01 → 2022-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥238m2021-04-01 → 2021-09-30Cons.Net cash provided by used in investment activities
Financing cash flow¥65m2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥1.2bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥320m2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥3.262022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥4.792022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥109.522021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥56.562021-04-01 → 2021-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥21.522021-07-01 → 2021-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥109.312021-04-01 → 2022-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥56.42021-04-01 → 2021-09-30Cons.Diluted earnings per share (5-year summary)
Equity ratio60.8%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio62.6%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio55.4%at 2021-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 31
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥2m
Reconciling Itemsreconcilingrevenue external2022-04-01 → 2022-09-30¥1m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥3m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥111m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥1.3bn
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥1.3bn
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥3m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥153m
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥4.3bn
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥4.3bn
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥187,000
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥92m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥5.5bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥5.5bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-09-30¥3m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥246m
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-09-30−¥6m
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-09-30−¥6m
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-09-30−¥97m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥3.1bn
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥3.1bn
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥6m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥1.6bn
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥3.6bn
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥3.6bn
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥261,000
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥117m
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-09-30¥6.7bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-09-30¥6.7bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-09-30¥6m
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-09-30¥1.7bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 513
ItemContextValueUnit
Other net ope cfPrior1YTDDuration48756000JPY
Other net ope cfCurrentYTDDuration37783000JPY
Subtotal ope cfPrior1YTDDuration967340000JPY
Subtotal ope cfCurrentYTDDuration-401821000JPY
Interest and dividends income received ope cf inv cfPrior1YTDDuration95000JPY
Interest and dividends income received ope cf inv cfCurrentYTDDuration188000JPY
Interest expenses paid ope cf fin cfPrior1YTDDuration-11073000JPY
Interest expenses paid ope cf fin cfCurrentYTDDuration-13063000JPY
Income taxes paid ope cfPrior1YTDDuration-119675000JPY
Income taxes paid ope cfCurrentYTDDuration-291364000JPY
Income taxes refund ope cfPrior1YTDDuration46281000JPY
Income taxes refund ope cfCurrentYTDDuration10247000JPY
Net cash provided by used in operating activitiesPrior1YTDDuration882968000JPY
Net cash provided by used in operating activitiesCurrentYTDDuration-695814000JPY
Payments into time deposits inv cfPrior1YTDDuration-JPY
Payments into time deposits inv cfCurrentYTDDuration-9000000JPY
Proceeds from redemption of securities inv cfPrior1YTDDuration-JPY
Proceeds from redemption of securities inv cfCurrentYTDDuration5951000JPY
Purchase of property plant and equipment inv cfPrior1YTDDuration-95898000JPY
Purchase of property plant and equipment inv cfCurrentYTDDuration-152271000JPY
Purchase of investments in subsidiaries resulting in change in scope of consolidation inv cfPrior1YTDDuration-135657000JPY
Purchase of investments in subsidiaries resulting in change in scope of consolidation inv cfCurrentYTDDuration-692193000JPY
Collection of loans receivable inv cfPrior1YTDDuration690000JPY
Collection of loans receivable inv cfCurrentYTDDuration94733000JPY
Proceeds from cancellation of insurance funds inv cfPrior1YTDDuration-JPY
Proceeds from cancellation of insurance funds inv cfCurrentYTDDuration155376000JPY
Other net inv cfPrior1YTDDuration-6985000JPY
Other net inv cfCurrentYTDDuration-3410000JPY
Net cash provided by used in investment activitiesPrior1YTDDuration-237850000JPY
Net cash provided by used in investment activitiesCurrentYTDDuration-600814000JPY
Redemption of bonds fin cfPrior1YTDDuration-216140000JPY
Redemption of bonds fin cfCurrentYTDDuration-7000000JPY
Increase decrease in short term loans payable fin cfPrior1YTDDuration85000000JPY
Increase decrease in short term loans payable fin cfCurrentYTDDuration400000000JPY
Proceeds from long term loans payable fin cfPrior1YTDDuration220000000JPY
Proceeds from long term loans payable fin cfCurrentYTDDuration-JPY
Repayment of long term loans payable fin cfPrior1YTDDuration-207246000JPY
Repayment of long term loans payable fin cfCurrentYTDDuration-212919000JPY
Repayments of lease obligations fin cfPrior1YTDDuration-8553000JPY
Repayments of lease obligations fin cfCurrentYTDDuration-8560000JPY
Payments for long term accounts payable other fin cfPrior1YTDDuration-65139000JPY
Payments for long term accounts payable other fin cfCurrentYTDDuration-8067000JPY
Purchase of treasury stock fin cfPrior1YTDDuration-76046000JPY
Purchase of treasury stock fin cfCurrentYTDDuration-JPY
Cash dividends paid fin cfPrior1YTDDuration-52103000JPY
Cash dividends paid fin cfCurrentYTDDuration-98531000JPY
Net cash provided by used in financing activitiesPrior1YTDDuration-320229000JPY
Net cash provided by used in financing activitiesCurrentYTDDuration64920000JPY
Effect of exchange rate change on cash and cash equivalentsPrior1YTDDuration-548000JPY
Effect of exchange rate change on cash and cash equivalentsCurrentYTDDuration7852000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass